U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula 2C37H48N4O8S2.3H2O
Molecular Weight 1535.904
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ODEVIXIBAT SESQUIHYDRATE

SMILES

O.O.O.CCCCC1(CCCC)CN(C2=CC=CC=C2)C3=CC(SC)=C(OCC(=O)N[C@@H](C(=O)N[C@@H](CC)C(O)=O)C4=CC=C(O)C=C4)C=C3S(=O)(=O)N1.CCCCC5(CCCC)CN(C6=CC=CC=C6)C7=CC(SC)=C(OCC(=O)N[C@@H](C(=O)N[C@@H](CC)C(O)=O)C8=CC=C(O)C=C8)C=C7S(=O)(=O)N5

InChI

InChIKey=UIYFGCAQGONAMU-ZHQCGWDOSA-N
InChI=1S/2C37H48N4O8S2.3H2O/c2*1-5-8-19-37(20-9-6-2)24-41(26-13-11-10-12-14-26)29-21-31(50-4)30(22-32(29)51(47,48)40-37)49-23-33(43)39-34(25-15-17-27(42)18-16-25)35(44)38-28(7-3)36(45)46;;;/h2*10-18,21-22,28,34,40,42H,5-9,19-20,23-24H2,1-4H3,(H,38,44)(H,39,43)(H,45,46);3*1H2/t2*28-,34+;;;/m00.../s1

HIDE SMILES / InChI

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C37H48N4O8S2
Molecular Weight 740.929
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

A-4250 (odevixibat) is a selective inhibitor of the ileal bile acid transporter (IBAT) that acts locally in the gut. Ileum absorbs glyco-and taurine-conjugated forms of the bile salts. IBAT is the first step in absorption at the brush-border membrane. A-4250 works by decreasing the re-absorption of bile acids from the small intestine to the liver, whichreduces the toxic levels of bile acids during the progression of the disease. It exhibits therapeutic intervention by checking the transport of bile acids. Studies show that A-4250 has the potential to decrease the damage in the liver cells and the development of fibrosis/cirrhosis of the liver known to occur in progressive familial intrahepatic cholestasis. A-4250 is a designated orphan drug in the USA for October 2012. A-4250 is a designated orphan drug in the EU for October 2016. A-4250 was awarded PRIME status for PFIC by EMA in October 2016. A-4250 is in phase II clinical trials by Albireo for the treatment of primary biliary cirrhosis (PBC) and cholestatic pruritus. In an open label Phase 2 study in children with cholestatic liver disease and pruritus, odevixibat showed reductions in serum bile acids and pruritus in most patients and exhibited a favorable overall tolerability profile.

Approval Year

PubMed

PubMed

TitleDatePubMed
The ileal bile acid transporter inhibitor A4250 decreases serum bile acids by interrupting the enterohepatic circulation.
2016 Jan

Sample Use Guides

The primary efficacy objective was to demonstrate the efficacy of once daily dosing of A-4250, 1.5–3 mg orally during a four-week treatment period to relieve patients with primary biliary cholangitis from cholestatic pruritus.
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Sat Dec 16 19:02:25 GMT 2023
Edited
by admin
on Sat Dec 16 19:02:25 GMT 2023
Record UNII
Q76KP2H4XW
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ODEVIXIBAT SESQUIHYDRATE
Common Name English
BYLVAY
Brand Name English
Odevixibat sesquihydrate [WHO-DD]
Common Name English
BUTANOIC ACID, 2-(((2R)-2-((2-((3,3-DIBUTYL-2,3,4,5-TETRAHYDRO-7-(METHYLTHIO)-1,1-DIOXIDO-5-PHENYL-1,2,5-BENZOTHIADIAZEPIN-8-YL)OXY)ACETYL)AMINO)-2-(4-HYDROXYPHENYL)ACETYL)AMINO)-, HYDRATE (2:3), (2S)-
Systematic Name English
Code System Code Type Description
SMS_ID
300000024551
Created by admin on Sat Dec 16 19:02:25 GMT 2023 , Edited by admin on Sat Dec 16 19:02:25 GMT 2023
PRIMARY
PUBCHEM
156028087
Created by admin on Sat Dec 16 19:02:25 GMT 2023 , Edited by admin on Sat Dec 16 19:02:25 GMT 2023
PRIMARY
CAS
2409081-01-0
Created by admin on Sat Dec 16 19:02:25 GMT 2023 , Edited by admin on Sat Dec 16 19:02:25 GMT 2023
PRIMARY
RXCUI
2563978
Created by admin on Sat Dec 16 19:02:25 GMT 2023 , Edited by admin on Sat Dec 16 19:02:25 GMT 2023
PRIMARY
FDA UNII
Q76KP2H4XW
Created by admin on Sat Dec 16 19:02:25 GMT 2023 , Edited by admin on Sat Dec 16 19:02:25 GMT 2023
PRIMARY
Related Record Type Details
ANHYDROUS->SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY